昔布类药物的心血管风险评价

下载PDF

导出

作者裴振峨

机构地区北京市药品不良反应监测中心

出处《临床药物治疗杂志》 2008年第5期59-62,共4页 Clinical Medication Journal

关键词昔布类药物心血管选择性COX-2抑制剂风险评价解热镇痛抗炎药胃肠道不良反应选择性抑制 COX-1

参考文献19

1[1]C.Battia,F.Cohzzi.Cox-2 inhibitors:pharmacaologocal data and adverse effects.Minerva.Anestesiol,2005,461-470
2[2]Pitt B,Pepine C,Willerson JT.COX-2 inhibition and cardiovascular events.Circulation,2002,106:167-169
3[3]Novartis & co.Prexige Investor Conference Call Shdes Results From TARGET
4[4]Krum H,Liew D,Aw J,et al.Cardiovascular effects of selective COX-2 inhibitors.Expert Rev Cardiovase Ther,2004,2(2):256-270
5[5]Brooks PM,Day RO.COX-2 inhibitors.Med J Aust,2000,173(8):433-436
6[6]Bombardier C,Laine L,Reicin A,et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.VIGOR Study Group.N Engl J Med,2000;343:1520-1528
7[7]Graham DJ,Calnpen D,Hui R,et al.Risk of acute myocardial infarction and sudden cardiac deathin patientstreatedwith cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs:nested case-control study.Lancet,2005,365:475-481
8[8]Juni P,Nartey L,Reichenbach S,et al.Risk of cardiovascular events and rofecoxib:cumulative meta-analysis.Lancet,2004,364:2021-2029
9[9]Hippisley-Cox J,Coupland C.Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitom or conventional nonsteroidal anti-inflammatory drugs:population based nested casecontrol analysis.BMJ,2005,330:1366
10[10]Bresalier RS,Sandier RS,Quan H,et al.Cardiovascular events associated with rofeeoxib in a colorectal adenoma chemoprevention trial.N Ensl J Med,2005,352:1092-1102

临床药物治疗杂志

2008年第5期

内容加载中请稍等...